1,665 Shares in Waters Corporation $WAT Purchased by Godshalk Welsh Capital Management Inc.

Godshalk Welsh Capital Management Inc. acquired a new stake in Waters Corporation (NYSE:WAT – Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,665 shares of the medical instruments supplier’s stock, valued at approximately $496,000.

Several other hedge funds have also recently added to or reduced their stakes in WAT. Pinnacle Associates Ltd. increased its stake in shares of Waters by 0.3% during the 4th quarter. Pinnacle Associates Ltd. now owns 7,608 shares of the medical instruments supplier’s stock worth $2,890,000 after purchasing an additional 26 shares in the last quarter. Exencial Wealth Advisors LLC lifted its position in shares of Waters by 1.7% in the fourth quarter. Exencial Wealth Advisors LLC now owns 1,681 shares of the medical instruments supplier’s stock valued at $638,000 after acquiring an additional 28 shares in the last quarter. Clearstead Advisors LLC lifted its position in shares of Waters by 5.1% in the fourth quarter. Clearstead Advisors LLC now owns 616 shares of the medical instruments supplier’s stock valued at $234,000 after acquiring an additional 30 shares in the last quarter. Avalon Trust Co boosted its stake in shares of Waters by 2.3% during the first quarter. Avalon Trust Co now owns 1,330 shares of the medical instruments supplier’s stock valued at $396,000 after acquiring an additional 30 shares during the last quarter. Finally, Integrated Wealth Concepts LLC boosted its stake in shares of Waters by 2.9% during the 1st quarter. Integrated Wealth Concepts LLC now owns 1,048 shares of the medical instruments supplier’s stock worth $386,000 after purchasing an additional 30 shares during the last quarter. 94.01% of the stock is currently owned by hedge funds and other institutional investors.

Get Waters alerts:

Waters Stock Performance

Waters stock opened at $370.93 on Thursday. Waters Corporation has a 12-month low of $275.05 and a 12-month high of $414.15. The company has a market capitalization of $36.42 billion, a price-to-earnings ratio of 47.13, a price-to-earnings-growth ratio of 2.22 and a beta of 1.20. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.79 and a quick ratio of 1.13. The firm’s fifty day moving average price is $363.34 and its 200 day moving average price is $345.93.

Waters (NYSE:WAT – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $2.70 EPS for the quarter, beating analysts’ consensus estimates of $2.31 by $0.39. Waters had a return on equity of 15.60% and a net margin of 11.91%.The firm had revenue of $1.27 billion during the quarter, compared to the consensus estimate of $1.20 billion. During the same quarter in the prior year, the business posted $2.25 earnings per share. Waters’s revenue for the quarter was up 91.4% on a year-over-year basis. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. On average, research analysts forecast that Waters Corporation will post 14.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

WAT has been the subject of a number of analyst reports. TD Cowen reissued a “hold” rating on shares of Waters in a research report on Wednesday, July 15th. JPMorgan Chase & Co. lifted their price target on Waters from $330.00 to $345.00 and gave the company a “neutral” rating in a report on Wednesday, May 6th. Robert W. Baird set a $387.00 price objective on shares of Waters in a research note on Wednesday, May 6th. Piper Sandler began coverage on shares of Waters in a research note on Thursday, June 11th. They set a “neutral” rating and a $400.00 price target on the stock. Finally, Wells Fargo & Company lifted their price target on shares of Waters from $355.00 to $370.00 and gave the company an “equal weight” rating in a report on Thursday, May 14th. Three analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $401.60.

View Our Latest Research Report on Waters

Waters Profile

(Free Report)

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.

See Also

• Five stocks we like better than Waters
• Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
• Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
• Moog Is More Than a Missile Maker, and Wall Street Is Noticing
• A Boring Dividend Growth Strategy Becomes a Solid Defensive Play

Want to see what other hedge funds are holding WAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Waters Corporation (NYSE:WAT – Free Report).

Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.